Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Teva
Mallinckrodt
Johnson and Johnson
Deloitte
Dow
Julphar
AstraZeneca
Fish and Richardson

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205934

« Back to Dashboard

NDA 205934 describes DOCETAXEL, which is a drug marketed by Accord Hlthcare, Actavis Llc, Amneal Pharms Co, Apotex Inc, Dfb Oncology Ltd, Dr Reddys Labs Ltd, Hospira Inc, Ingenus Pharms Llc, Jiangsu Hengrui Med, Mylan Labs Ltd, Pfizer Labs, Sandoz, Teva Pharms Usa, and Eagle Pharms, and is included in fifteen NDAs. It is available from fifteen suppliers. There are two patents protecting this drug. Additional details are available on the DOCETAXEL profile page.

The generic ingredient in DOCETAXEL is docetaxel. There are forty drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
Summary for 205934
Tradename:DOCETAXEL
Applicant:Eagle Pharms
Ingredient:docetaxel
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 205934
Physiological EffectMicrotubule Inhibition
Suppliers and Packaging for NDA: 205934
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOCETAXEL docetaxel SOLUTION;IV (INFUSION) 205934 NDA Eagle Pharmaceuticals, Inc. 42367-121 N 42367-121-21
DOCETAXEL docetaxel SOLUTION;IV (INFUSION) 205934 NDA Eagle Pharmaceuticals, Inc. 42367-121 N 42367-121-25

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength20MG/ML (20MG/ML)
Approval Date:Dec 22, 2015TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2033Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength80MG/4ML (20MG/ML)
Approval Date:Dec 22, 2015TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
UBS
Citi
QuintilesIMS
Federal Trade Commission
AstraZeneca
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.